Trevi Therapeutics Future Growth
Future criteria checks 0/6
Trevi Therapeutics's earnings are forecast to decline at 9.6% per annum while its annual revenue is expected to grow at 77.6% per year. EPS is expected to decline by 4.8% per annum.
Key information
-9.6%
Earnings growth rate
-4.8%
EPS growth rate
| Pharmaceuticals earnings growth | 23.5% |
| Revenue growth rate | 77.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -78 | -64 | N/A | 5 |
| 12/31/2025 | N/A | -54 | -57 | N/A | 5 |
| 12/31/2024 | N/A | -41 | -47 | -39 | 5 |
| 12/31/2023 | N/A | -29 | -32 | -32 | N/A |
| 9/30/2023 | N/A | -27 | -32 | -32 | N/A |
| 6/30/2023 | N/A | -27 | -33 | -33 | N/A |
| 3/31/2023 | N/A | -28 | -29 | -29 | N/A |
| 12/31/2022 | N/A | -29 | -28 | -28 | N/A |
| 9/30/2022 | N/A | -32 | -28 | -28 | N/A |
| 6/30/2022 | N/A | -31 | -27 | -27 | N/A |
| 3/31/2022 | N/A | -33 | -28 | -28 | N/A |
| 12/31/2021 | N/A | -34 | -29 | -29 | N/A |
| 9/30/2021 | N/A | -35 | -32 | -32 | N/A |
| 6/30/2021 | N/A | -35 | -31 | -31 | N/A |
| 3/31/2021 | N/A | -33 | -32 | -32 | N/A |
| 12/31/2020 | N/A | -33 | -29 | -29 | N/A |
| 9/30/2020 | N/A | -30 | -26 | -26 | N/A |
| 6/30/2020 | N/A | -30 | -27 | -27 | N/A |
| 3/31/2020 | N/A | -29 | -24 | -24 | N/A |
| 12/31/2019 | N/A | -27 | -23 | -23 | N/A |
| 9/30/2019 | N/A | -28 | -22 | -22 | N/A |
| 6/30/2019 | N/A | -27 | -18 | -18 | N/A |
| 3/31/2019 | N/A | -27 | -19 | -18 | N/A |
| 12/31/2018 | N/A | -26 | -18 | -18 | N/A |
| 9/30/2018 | N/A | -22 | -16 | -16 | N/A |
| 12/31/2017 | N/A | -13 | -8 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRVI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRVI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRVI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRVI is forecast to have no revenue next year.
High Growth Revenue: TRVI is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRVI's Return on Equity is forecast to be high in 3 years time